NCCN《软组织肉瘤临床实践指南(2018年第1版)》胃肠间质瘤内容更新介绍与解读

Updates and interpretations of the NCCN Clinical Practice Guidelines(2018 first version) on gastrointestinal stromal tumor

胃肠间质瘤(GIST)的诊断和治疗已日趋标准化和规范化。近10余年来,随着分子水平发病机制的揭示和小分子酪氨酸激酶受体抑制剂的成功应用,GIST治疗已经成为精准医疗时代最经典的实体肿瘤靶向治疗成功范例之一。2017年10月,美国国家综合癌症网络(NCCN)发布了最新版的《软组织肉瘤临床实践指南(2018年第1版)》,与既往版本相比,新版指南中GIST部分内容更新较多,涵盖了从诊断到治疗以及随访的GIST病人全程管理。

The diagnosis and treatment of gastrointestinal stromal tumor （GIST） is getting more and more standardized. In the last decade, due to the revelation of the molecular mechanism of its tumorigenesis, as well as the effectiveness of tyrosine kinase inhibitors, GIST has become well known as one of the most classical model of targeted therapy on solid tumor in the precision medicine era. The National Comprehensive Cancer Network （NCCN） issued the latest version of clinical practice guideline on soft tissue sarcoma in October 2017. Compared with previous versions, the new version of the guideline has many updates on the field of GIST, covering the whole-course management of GIST patients from diagnosis to treatment and follow-up.